文献速递头颈外科

循环肿瘤HPV DNA在HPV阳性口咽癌管理中的作用及其与MRI的相关性

Circulating tumor HPV DNA in the management of HPV+ oropharyngeal cancer and its correlation with MRI.
PubMed 文献 · Head Neck · 2024-07-09

本研究在117例诊断时患者中比较ddPCR检测ctHPVDNA与p16免疫组化和定性HPV PCR,并行纵向血样检测复发关联,结合临床特征与MRI肿瘤大小测量进行多维评估。结果显示ctHPVDNA诊断敏感性100%(95%CI 95.5-100)、特异性94.4(95%CI 81.3-99.3),随访中检测复发敏感性100%、特异性98.4%,且与颈淋巴结转移体积及原发灶与颈淋巴结转移体积之和相关。

要点

  • 诊断时ctHPVDNA敏感性100%(95%CI 95.5-100),特异性94.4(95%CI 81.3-99.3)。
  • 随访中ctHPVDNA检测复发敏感性100%、特异性98.4%、NPV 100%。
  • ctHPVDNA与颈淋巴结转移体积及原发灶与颈淋巴结转移体积之和相关。

核心结论

  • ctHPVDNA在诊断时识别HPV相关口咽鳞状细胞癌优于p16。
  • 将ctHPVDNA引入诊断之外场景,为改善口咽鳞状细胞癌患者随访方案提供重要机会。

研究设计与样本

  • 研究在诊断时纳入117例患者,治疗前及随访期间采集血浆样本。
  • 采用ddPCR检测HPV16、HPV33和HPV35的E6。
  • 进行纵向血样采样以检测ctHPVDNA与组织学确诊复发的关联。
  • 进行多维评估,包括临床特征、ctHPVDNA及基于MRI的原发肿瘤和颈部淋巴结转移大小测量。

主要发现

  • 诊断时ctHPVDNA敏感性100%(95%CI 95.5-100),特异性94.4(95%CI 81.3-99.3),阳性预测值94.4(95%CI 81.3-99.3),阴性预测值100%(95%CI 89.7-100)。
  • 随访期间ctHPVDNA检测复发敏感性100%(95%CI 72.1-100),特异性98.4%(95%CI 91.7-100),阳性预测值90.9%(95%CI 62.3-98.4),阴性预测值100%(95%CI 94.3-100)。
  • 观察到ctHPVDNA与颈部淋巴结转移体积及原发肿瘤与颈部淋巴结转移体积之和相关。

关键数值与推荐

  • 诊断时ctHPVDNA敏感性100%(95%CI 95.5-100),特异性94.4(95%CI 81.3-99.3)。
  • 随访中ctHPVDNA检测复发敏感性100%(95%CI 72.1-100),特异性98.4%(95%CI 91.7-100)。

临床怎么用

  • ctHPVDNA在诊断时识别HPV相关口咽鳞状细胞癌优于p16。
  • 将ctHPVDNA引入诊断之外场景,为改善口咽鳞状细胞癌患者随访方案提供重要机会。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: First aim was to compare ddPCR assays of ctHPVDNA with p16 IHC and qualitative HPV PCR. Second aim was to carry out longitudinal blood sampling to test for association of ctHPVDNA with histological confirmed recurrence. Third aim was to perform a multidimensional assessment which included: (1) clinical features; (2) ctHPVDNA; (3) MRI-based tumor size measurements of primary tumor (PT) and cervical lymph node metastases (CLNM). METHODS: Plasma samples were collected before treatment and during follow-up, and ddPCR assay comprising E6 of HPV16 and HPV 33 and HPV 35 was used. RESULTS: Present study was conducted at diagnosis in 117 patients and revealed a ctHPVDNA sensitivity of 100% (95% CI 95.5-100) and a specificity of 94.4 (95% CI 81.3-99.3), positive predictive value (PPV) of 94.4 (95% CI 81.3-99.3), and negative predictive value (NPP) of 100% (95% CI 89.7-100). During follow-up ctHPVDNA had a sensitivity of 100% (95% CI 72.1-100)% and specificity of 98.4% (95% CI 91.7-100)%, PPV% of 90.9% (95% CI 62.3-98.4) and NPV% of 100% (95% CI 94.3-100) for ability to detect recurrence. Correlation between both the CLNM volume and the sum of PT and CLNM volume was observed. CONCLUSIONS: ctHPVDNA was superior to p16 in identification of HPV-OPSCC at diagnosis. Introduction of ctHPVDNA, beyond diagnostic setting, represents a great opportunity to improve follow-up protocol of OPSCC patients.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Campo F, Paolini F, Manciocco V, et al. Circulating tumor HPV DNA in the management of HPV+ oropharyngeal cancer and its correlation with MRI. Head Neck. 2024. PMID: 38979763. doi:10.1002/hed.27866

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。